Daniel E. Cohen

4.6k citations

55 papers · 1.6k indexed · h-index 19

Impact in

Hepatology top 0.5%
- Hepatitis C virus research
- Liver Disease and Transplantation
Epidemiology top 2%
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- HIV, Drug Use, Sexual Risk

Papers in ⓘ

Hepatology 49
- Hepatitis C virus research 49
Infectious Diseases 21
- HIV/AIDS drug development and treatment 19

Co-authors: Thomas Podsadecki (20 shared papers)Barry Bernstein (11 shared papers)Eric Lawitz (6 shared papers)Edward Tam (11 shared papers)Rajeev Menon (10 shared papers)Lois Larsen (7 shared papers)Kris V. Kowdley (5 shared papers)Fred Poordad (7 shared papers)
Journals: Journal of Hepatology (8 papers)Journal of Viral Hepatitis (5 papers)The American Journal of Gastroenterology (4 papers)The Journal of Infectious Diseases (3 papers)Gastroenterology (3 papers)
Partner nations: United States Germany France

In The Last Decade

Daniel E. Cohen

54 papers receiving 1.6k citations

Peers

Countries citing papers authored by Daniel E. Cohen

Since Specialization

Citations

This map shows the geographic impact of Daniel E. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Cohen more than expected).

Fields of papers citing papers by Daniel E. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Cohen. The network helps show where Daniel E. Cohen may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel E. Cohen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel E. Cohen Line = papers co-authored together Daniel E. Cohen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C New England Journal of Medicine ·Fred Poordad, Eric Lawitz, Kris V. Kowdley, Daniel E. Cohen, Thomas Podsadecki, Sara Siggelkow, M. Heckaman, Lois Larsen, Rajeev Menon, Gennadiy Koev, Rakesh Tripathi, Edward Tam, Barry Bernstein	2013	214
2	Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease Gastroenterology ·Paul J. Pockros, K. Rajender Reddy, Parvez Mantry, E. Cohen, Michael Bennett, Mark Sulkowski, David Bernstein, Daniel E. Cohen, Nancy S. Shulman, Deli Wang, Amit Khatri, Manal Abunimeh, Thomas Podsadecki, Eric Lawitz	2016	197
3	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 New England Journal of Medicine ·Kris V. Kowdley, Eric Lawitz, Fred Poordad, Daniel E. Cohen, David R. Nelson, Stefan Zeuzem, Gregory T. Everson, Paul Y. Kwo, Graham R. Foster, Mark Sulkowski, Wangang Xie, Edward Tam, George Liossis, Lois Larsen, Amit Khatri, Thomas Podsadecki, Barry Bernstein	2014	185
4	In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450 Antimicrobial Agents and Chemotherapy ·Edward Tam, Rakesh Tripathi, Daniel E. Cohen, I. Gaultier, Tatyana Dekhtyar, Liangjun Lu, Thomas Reisch, Michelle Irvin, Todd A. Hopkins, Ron Pithawalla, Timothy Middleton, Teresa I. Ng, Keith F. McDaniel, Yat Sun Or, Rajeev Menon, Dale J. Kempf, Akhteruzzaman Molla, Christine A. Collins	2014	102
5	Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine Journal of Hepatology ·Jacob Lalezari, J. Greg Sullivan, Peter Varunok, E M van Galen, Kris V. Kowdley, Vinod K. Rustgi, Humberto Aguilar, Franco Felizarta, Barbara McGovern, Martin King, Akshanth R. Polepally, Daniel E. Cohen	2015	88
6	Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir Antimicrobial Agents and Chemotherapy ·Preethi Krishnan, Rakesh Tripathi, Gretja Schnell, Thomas Reisch, Jill Beyer, Michelle Irvin, Wangang Xie, Lois Larsen, Daniel E. Cohen, Thomas Podsadecki, Edward Tam, Christine A. Collins	2015	77
7	Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and Dasabuvir American Journal of Transplantation ·Prajakta Badri, Sheetij Dutta, Eoin Coakley, Daniel E. Cohen, Bifeng Ding, Thomas Podsadecki, Barry Bernstein, Walid M. Awni, Rajeev Menon	2015	62
8	LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study Journal of Hepatology ·Paul J. Pockros, K. Rajender Reddy, Parvez Mantry, E. Cohen, Michael Bennett, Mark Sulkowski, David Bernstein, Thomas Podsadecki, Daniel E. Cohen, Nancy S. Shulman, D. Wang, Amit Khatri, Manal Abunimeh, Eric Lawitz	2015	60
9	A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1 Journal of Hepatology ·Eric Lawitz, Fred Poordad, Kris V. Kowdley, Daniel E. Cohen, Thomas Podsadecki, Sara Siggelkow, Lois Larsen, Rajeev Menon, Gennadiy Koev, Rakesh Tripathi, Edward Tam, Barry Bernstein	2013	55
10	1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS Journal of Hepatology ·F. Poordad, E. Läwitz, K.V. Kowdley, Gregory T. Everson, B. Freilich, Daniel E. Cohen, Sara Siggelkow, M. Heckaman, Rajeev Menon, T Matias, Thomas Podsadecki, Barry Bernstein	2012	54
11	Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen Antiviral Therapy ·Stéphane Chevaliez, Jordan J. Feld, Yeu-Yao Cheng, Heiner Wedemeyer, Christoph Sarrazin, Benjamin Maasoumy, Christine Herman, John Hackett, Daniel E. Cohen, George J. Dawson, Jean–Michel Pawlotsky, Gavin Cloherty	2016	49
12	3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY Journal of Hepatology ·K.V. Kowdley, E. Läwitz, F. Poordad, Daniel E. Cohen, Daniel W. Nelson, Stefan Zeuzem, Gregory T. Everson, Paul Y. Kwo, Graham R. Foster, Mark Sulkowski, Wen-Rui Xie, Lis Kjær Larsen, Arun Khatri, Thomas Podsadecki, Barry Bernstein	2013	47
13	Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy Journal of Virological Methods ·Christoph Sarrazin, Heiner Wedemeyer, Gavin Cloherty, Daniel E. Cohen, Stéphane Chevaliez, Christine Herman, Barry Bernstein, Jean–Michel Pawlotsky	2014	37
14	Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial The Lancet. Gastroenterology & hepatology ·Tania M. Welzel, Tarik Asselah, Emily O. Dumas, Stefan Zeuzem, David Shaw, Rawi Hazzan, Xavier Forns, Edward Tam, Wenjing Lü, Daniel E. Cohen, Jordan J. Feld	2017	33
15	HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients Journal of Virological Methods ·Jürgen K. Rockstroh, Jordan J. Feld, Stéphane Chevaliez, Yeu-Yao Cheng, Heiner Wedemeyer, Christoph Sarrazin, Benjamin Maasoumy, Christine Herman, John Hackett, Daniel E. Cohen, George J. Dawson, Gavin Cloherty, Jean–Michel Pawlotsky	2017	28
16	Prevalence of Hepatitis C Virus Infection among Men Who Have Sex with Men at a Boston Community Health Center and Its Association with Markers of High-Risk Behavior AIDS Patient Care and STDs ·Daniel E. Cohen, Christopher J. Russell, Sarit A. Golub, Kenneth H. Mayer	2006	27
17	Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study Clinical Infectious Diseases ·Fred Poordad, Kosh Agarwal, Ziad Younes, Daniel E. Cohen, Wangang Xie, Thomas Podsadecki	2014	23
18	Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials Infectious Diseases and Therapy ·Darshan Mehta, E. Cohen, Mariem Charafeddine, Daniel E. Cohen, Yanjun Bao, Yuri Sánchez González, Tram T. Tran	2017	21
19	Serum miR‐122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR‐122 in HCV‐infected subjects Journal of Viral Hepatitis ·Jeffrey F. Waring, Emily O. Dumas, Sylvie Abel, Eoin Coakley, Daniel E. Cohen, J. Wade Davis, Thomas Podsadecki, Sheetij Dutta	2015	21
20	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease Kidney International Reports ·Eric Lawitz, Edward Gane, E. Cohen, John M. Vierling, Kosh Agarwal, Tarek Hassanein, Parvez Mantry, Paul J. Pockros, Michael Bennett, Nyingi Kemmer, Giuseppe Morelli, Jiuhong Zha, Deli Wang, Nancy S. Shulman, Daniel E. Cohen, K. Rajender Reddy	2018	17

About Daniel E. Cohen

Daniel E. Cohen is a scholar working on Hepatology, Infectious Diseases, Epidemiology, Virology and Transplantation, having authored 55 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hepatitis C virus research (49 papers), Liver Disease Diagnosis and Treatment (23 papers), Hepatitis B Virus Studies (22 papers), HIV/AIDS drug development and treatment (19 papers), Chronic Lymphocytic Leukemia Research (5 papers), Systemic Lupus Erythematosus Research (5 papers), HIV Research and Treatment (4 papers) and Renal Transplantation Outcomes and Treatments (2 papers). The work is most often cited by research in Hepatology (1.4k citations), Epidemiology (1.3k citations), Infectious Diseases (491 citations), Transplantation (52 citations) and Virology (37 citations). Daniel E. Cohen has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Thomas Podsadecki, Barry Bernstein, Eric Lawitz, Edward Tam, Rajeev Menon, Lois Larsen, Kris V. Kowdley, Fred Poordad, Mark Sulkowski and Rakesh Tripathi. Their work appears in journals such as Journal of Hepatology, Journal of Viral Hepatitis, The American Journal of Gastroenterology, The Journal of Infectious Diseases and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact